Email this article NEW TREATMENT STANDARD FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- Authors: Alekseev B.Y.1
-
Affiliations:
- National Medical Research Center of Radiology, Ministry of Health of Russia
- Issue: Vol 14, No 3 (2018)
- Pages: 68-77
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.09.2018
- URL: https://oncourology.abvpress.ru/oncur/article/view/880
- DOI: https://doi.org/10.17650/1726-9776-2018-14-3-68-77
- ID: 880
Cite item
Full Text
Abstract
Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen level are at high risk for metastasis. Until recently there was no standard of treatment for this category of patients. A total of 1401 patients with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less underwent randomization to double-blind, phase III PROSPER trial. Patients were continuing androgen-deprivation therapy in combination with enzalutamide (at a dose of 160 mg) or placebo once daily. The median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group. Enzalutamide treatment resulted in a 71 % lower risk of radiographic progression or death than did placebo (hazard ratio 0.29; 95 % confidence interval 0.24 to 0.35; p <0.001). Adverse events were consistent with the established safety profile of enzalutamide.
About the authors
B. Ya. Alekseev
National Medical Research Center of Radiology, Ministry of Health of Russia
Author for correspondence.
Email: byalekseev@mail.ru
ORCID iD: 0000-0002-3398-4128
3 2nd Botkinskiy Proezd, Moscow 125284. Russian Federation
References
- State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 236 p. (In Russ.).
- EAU guidelines 2018. Available at: http://uroweb.org/guidelines/.
- Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12.
- Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. doi: 10.1056/NEJMoa1209096. PMID: 23228172.
- Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(18):424–33. doi: 10.1056/NEJMc1410239. PMID: 25354111.
- Xie W., Regan M.M., Buyse M. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 2017;35(27):3097–104. doi: 10.1200/JCO.2017.73.9987. PMID: 28796587.
- Smith M.R., Kabbinavar F., Saad F. et al. Natural history of rising serum prostate-specific antigen in men with castrate non-metastatic prostate cancer. J Clin Oncol 2005;23:2918–25. doi: 10.1200/JCO.2005.01.529. PMID: 15860850.
- Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077–85. doi: 10.1002/cncr.25762. PMID: 21523719.
- Smith M.R., Saad F., Oudard S. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-re-sistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31(30):3800–6. doi: 10.1200/JCO.2012.44.6716. PMID: 24043751.
- NCCN guidelines version 2.2017. February 21, 2017. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx
- Smith M.R., Saad F., Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379(9810):39–46. doi: 10.1016/S0140-6736(11)61226-9. PMID: 22093187.
- Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506. PMID: 22894553.
- Penson D.F., Armstrong A.J., Concepcion R. et al. Еnzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 2016;34(18):2098–106. doi: 10.1200/JCO.2015.64.9285. PMID: 26811535.
- Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castrate-resistant prostate cancer. N Engl J Med 2018;378:2465–74.
- NCCN guidelines 2018. Available at: https://www.nccn.org/professionals/physi-cian_gls/default.aspx.
- AUA guidelines 2018. Available at: https://www.auanet.org/guidelines/prostate-cancer-castration-resistant-(2013-amen-ded-2018).
Supplementary files
